Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b, Multicenter, Dose Escalation, Evaluation of Safety and Tolerability of ASP7317 for Geographic Atrophy Secondary to Age-related Macular Degeneration

NCT03178149 is registered in ClinicalTrials.gov with Astellas Institute for Regenerative Medicine as lead sponsor.

NCT NCT03178149
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03178149 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b, Multicenter, Dose Escalation, Evaluation of Safety and Tolerability of ASP7317 for Geographic Atrophy Secondary to Age-related Macular Degeneration
Lead sponsor
Astellas Institute for Regenerative Medicine
Phase
Phase 1
Overall status
Recruiting
Start date
July 13, 2018
Completion date
December 31, 2027
Enrollment
42 (estimated)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

age-related macular degeneration